Friday, May 06, 2022 1:00:18 PM
Rose, You are 100% correct - in principle - even it were based on fraud - the Du ruling should not have damaged Amarin at all - as it is addressing a different health issue.
-----------------------
But that is theory - what we have experienced as 'Realty' - is that neither Generics or the US health system general 'Give a Damn' - what is on the label - or the name of the Icosapent Ethyl.
And what does 'Skinny Label' even mean. If what the patient wants is Icosapent Ethyl - the US logistic systems will 'automatically' provide him the cheapest Generic version (which you would have to guess right now is DR Reddy who has overtaken Hikma in no time).
Amarin and we as investors can scream as much as we like - no one really cares in the Systems - as it happens all over the place - all the time.
Generics are aloud to use every dirty trick in the book - WHY: It helps the States and Insurance companies save money on healthcare - end of story.
------------------------
Our immediate hope lies with Marjac and SCOTUS. Even this is naturally 'a long shot' (given the small number aloud through) - it is in fact precisely this problem he is addressing in his 'big filing' as I understand it.
Courts 'looking the other way' when generics cheat (the nice version) - because is is 'what the people on the hill wants'.
-----------------------
But that is theory - what we have experienced as 'Realty' - is that neither Generics or the US health system general 'Give a Damn' - what is on the label - or the name of the Icosapent Ethyl.
And what does 'Skinny Label' even mean. If what the patient wants is Icosapent Ethyl - the US logistic systems will 'automatically' provide him the cheapest Generic version (which you would have to guess right now is DR Reddy who has overtaken Hikma in no time).
Amarin and we as investors can scream as much as we like - no one really cares in the Systems - as it happens all over the place - all the time.
Generics are aloud to use every dirty trick in the book - WHY: It helps the States and Insurance companies save money on healthcare - end of story.
------------------------
Our immediate hope lies with Marjac and SCOTUS. Even this is naturally 'a long shot' (given the small number aloud through) - it is in fact precisely this problem he is addressing in his 'big filing' as I understand it.
Courts 'looking the other way' when generics cheat (the nice version) - because is is 'what the people on the hill wants'.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
